 Connection
Myron Levin to Clinical Trials as Topic
This is a "connection" page, showing publications Myron Levin has written about Clinical Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.699 |
|
|
|
-
Lindsey JC, Shah SK, Siberry GK, Jean-Philippe P, Levin MJ. Ethical tradeoffs in trial design: case study of an HPV vaccine trial in HIV-infected adolescent girls in lower income settings. Dev World Bioeth. 2013 Aug; 13(2):95-104.
Score: 0.326
-
Levin MJ, Weinberg A. Immune responses to zoster vaccines. Hum Vaccin Immunother. 2019; 15(4):772-777.
Score: 0.121
-
Frazer IH, Levin MJ. Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer. Curr Opin Virol. 2011 Oct; 1(4):268-79.
Score: 0.073
-
Levin MJ. Varicella vaccination of immunocompromised children. J Infect Dis. 2008 Mar 01; 197 Suppl 2:S200-6.
Score: 0.057
-
Levin MJ. Use of varicella vaccines to prevent herpes zoster in older individuals. Arch Virol Suppl. 2001; (17):151-60.
Score: 0.035
-
Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M. Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother. 2013 May; 9(5):1177-84.
Score: 0.020
-
Toback SL, Levin MJ, Block SL, Belshe RB, Ambrose CS, Falloon J. Quadrivalent Ann Arbor strain live-attenuated influenza vaccine. Expert Rev Vaccines. 2012 Nov; 11(11):1293-303.
Score: 0.020
-
Levin MJ, Zaia JA, Hershey BJ, Davis LG, Robinson GV, Segreti AC. Topical acyclovir treatment of herpes zoster in immunocompromised patients. J Am Acad Dermatol. 1985 Oct; 13(4):590-6.
Score: 0.012
-
Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain. 2004 Aug; 5(6):344-56.
Score: 0.011
-
Dankner WM, Lindsey JC, Levin MJ. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J. 2001 Jan; 20(1):40-8.
Score: 0.009
-
Dworkin RH, Carrington D, Cunningham A, Kost RG, Levin MJ, McKendrick MW, Oxman MN, Rentier B, Schmader KE, Tappeiner G, Wassilew SW, Whitley RJ. Assessment of pain in herpes zoster: lessons learned from antiviral trials. Antiviral Res. 1997 Jan; 33(2):73-85.
Score: 0.007
-
Douglas JM, Judson FN, Levin MJ, Bosso JA, Spruance SL, Johnston JM, Corey L, McMillan JA, Weiner LB, Frank JA. A placebo-controlled trial of topical 8% arildone cream early in recurrent genital herpes. Antimicrob Agents Chemother. 1986 Mar; 29(3):464-7.
Score: 0.003
-
Meyers JD, Leszczynski J, Zaia JA, Flournoy N, Newton B, Snydman DR, Wright GG, Levin MJ, Thomas ED. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med. 1983 Apr; 98(4):442-6.
Score: 0.003
-
Zaia JA, Levin MJ, Preblud SR, Leszczynski J, Wright GG, Ellis RJ, Curtis AC, Valerio MA, LeGore J. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis. 1983 Apr; 147(4):737-43.
Score: 0.003
-
Meyers JD, Wade JC, Mitchell CD, Saral R, Lietman PS, Durack DT, Levin MJ, Segreti AC, Balfour HH. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med. 1982 Jul 20; 73(1A):229-35.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|